Mallinckrodt Pharmaceuticals
Edit

Mallinckrodt Pharmaceuticals

http://www.mallinckrodt.com/
Last activity: 12.03.2024
Categories: ActiveCareDevelopmentDrugLearnLifeMedtechProductSpecialtyWebsite
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, nephrology, pulmonology and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines and active pharmaceutical ingredients. Together, we’re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago – quality, integrity and service. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Equal Opportunity Employer Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
Followers
65.08K
Website visits
28.3K /mo.
Mentions
41
Location: United States, New Jersey
Employees: 1001-5000
Founded date: 1867

Investors 3

Mentions in press and media 41

DateTitleDescriptionSource
12.03.2024Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030...Opioid Use Disorder (OUD) Market Opioid Use Disorder Market Analysis, Industry Trends and Growth Out...einpresswi...
10.10.2023Mallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1...-wsj.com/ar...
12.05.2023API Innovation Center to Solidify U.S. Active Pharmaceutical...API Innovation Center Announced Agreement to Accelerate Adoption of Low-Cost Pharmaceutical Manufact...einpresswi...
20.09.2022Prevent Blindness Declares Second Annual Inflammatory Eye Di...Prevent Blindness declares Sept. 26 – Oct. 2, 2022, as the second annual Inflammatory Eye Disease (I...prweb.com/...
17.06.2022Attorney General Tong Announces $230 Million Settlement with...Press Releases 06/17/2022 Attorney General Tong Announces $230 Million Settlement with Mallinckrodt ...einpresswi...
22.02.2022Mallinckrodt chalks up CRL to packaging and labeling facilit...Mallinckrodt has been handed a complete response letter in connection to its NDA seeking approval fo...endpts.com...
12.11.2021The National Alliance for Caregiving Releases a New White Pa...The paper discuses significant components that contribute to systemic setbacks, including specifics ...prweb.com/...
28.10.2021Mallinckrodt and Terumo Blood and Cell Technologies Announce...- In a dual-review process, two independent advisory committees to the Australian Minister for Healt...marketscre...
21.09.2021Prevent Blindness Declares First-ever Inflammatory Eye Disea...Prevent Blindness has declared Sept. 27 – Oct. 3, 2021, as "Inflammatory Eye Disease Awareness ...prweb.com/...
03.09.2021Mallinckrodt Reaches Settlements with the Official Committee...prnewswire...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In